5-Aminoimidazole-4-carboxyamide-ribonucleoside (AICAR)- stimulated hepatic expression of Cyp4a10, Cyp4a14, Cyp4a31, and other peroxisome proliferator-activated receptor α-responsive mouse genes is AICAR 5′-monophosphate-dependent and AMP-activated protein kinase-independent

Journal of Pharmacology and Experimental Therapeutics

Volumn 339, Issue 3, 2011, Pages 886-895

  Bumpus, Namandjé N ^a   Johnson, Eric F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE PHOSPHATE; 5 IODOTUBERCIDIN; 6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; ACYL COA OXIDASE 1; ADENOSINE; ADENOSINE KINASE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; CARNITINE PALMITOYLTRANSFERASE I; CARNITINE PALMITOYLTRANSFERASE IA; CYTOCHROME P450 4A; CYTOCHROME P450 4A10; CYTOCHROME P450 4A14; CYTOCHROME P450 4A31; DORSOMORPHIN; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 1; FATTY ACID SYNTHASE; GENE PRODUCT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE; MESSENGER RNA; OLEIC ACID; OLEOYL COENZYME A; OLEOYL COENZYME A SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ACADM GENE; ACOX1 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; CPT1A GENE; CYTOCHROME P450 4A10 GENE; CYTOCHROME P450 4A14 GENE; CYTOCHROME P450 4A31 GENE; CYTOCHROME P450 4F13 GENE; CYTOCHROME P450 4F15 GENE; CYTOCHROME P450 4F16 GENE; CYTOCHROME P450 4F17 GENE; ENZYME INHIBITION; FABP1 GENE; FATTY ACID HYDROXYLATION; FATTY ACID METABOLISM; GENE; GENE EXPRESSION; HYDROXYLATION; IC 50; LIVER CELL; LIVER METABOLISM; LIVER MICROSOME METABOLISM; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACOLOGICAL BLOCKING; PHOSPHORYLATION; PRIORITY JOURNAL;

ADENOSINE; AMINOIMIDAZOLE CARBOXAMIDE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; COENZYME A LIGASES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME ACTIVATION; FATTY ACIDS, NONESTERIFIED; GENETIC VECTORS; HEPATOCYTES; HYDROXYLATION; LAURIC ACIDS; LIVER; MALE; MICE; MICE, INBRED C57BL; MICROSOMES, LIVER; PPAR ALPHA; RIBONUCLEOTIDES;

EID: 81555204264     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.184242     Document Type: Article

References (36)

1. Alexandre A, Rossi CR, Sartorelli L, and Siliprandi N (1969) The action of atractyloside and AMP on long-chain fatty acid oxidation and on the ATP-dependent fatty acid thiokinase. FEBS Lett 3:279-282.
2. Askari B, Kanter JE, Sherrid AM, Golej DL, Bender AT, Liu J, Hsueh WA, Beavo JA, Coleman RA, and Bornfeldt KE (2007) Rosiglitazone inhibits acyl-CoA synthetase activity and fatty acid partitioning to diacylglycerol and triacylglycerol via a peroxisome proliferator-activated receptor-γ- independent mechanism in human arterial smooth muscle cells and macrophages. Diabetes 56:1143-1152. (Pubitemid 46525070)
3. Aymerich I, Foufelle F, Ferré P, Casado FJ, and Pastor-Anglada M (2006) Extracellular adenosine activates AMP-dependent protein kinase (AMPK). J Cell Sci 119:1612-1621. (Pubitemid 43732987)
4. Beis I and Newsholme EA (1975) The contents of adenine nucleotides, phosphagens and some glycolytic intermediates in resting muscles from vertebrates and invertebrates. Biochem J 152:23-32.
5. Cantó C and Auwerx J (2010) AMP-activated protein kinase and its downstream transcriptional pathways. Cell Mol Life Sci 67:3407-3423.
6. Cool B, Zinker B, Chiou W, Kifle L, Cao N, Perham M, Dickinson R, Adler A, Gagne G, Iyengar R, et al. (2006) Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab 3:403-416. (Pubitemid 43811782)
7. Desvergne B, Michalik L, and Wahli W (2006) Transcriptional regulation of metabolism. Physiol Rev 86:465-514.
8. Ellis JM, Frahm JL, Li LO, and Coleman RA (2010) Acyl-coenzyme A synthetases in metabolic control. Curr Opin Lipidol 21:212-217.
9. Forman BM, Chen J, and Evans RM (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc Natl Acad Sci U S A 94:4312-4317.
10. Guigas B, Taleux N, Foretz M, Detaille D, Andreelli F, Viollet B, and Hue L (2007) AMP-activated protein kinase-independent inhibition of hepatic mitochondrial oxidative phosphorylation by AICA riboside. Biochem J 404:499-507.
11. Hardie DG, Hawley SA, and Scott JW (2006) AMP-activated protein kinase-development of the energy sensor concept. J Physiol 574:7-15.
12. Hardwick JP (2008) Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. Biochem Pharmacol 75:2263-2275.
13. Haynes CA, Allegood JC, Sims K, Wang EW, Sullards MC, and Merrill AH Jr (2008) Quantitation of fatty acyl-coenzyme As in mammalian cells by liquid chromatography-electrospray ionization tandem mass spectrometry. J Lipid Res 49:1113-1125.
14. Henderson JF, Paterson AR, Caldwell IC, Paul B, Chan MC, and Lau KF (1972) Inhibitors of nucleoside and nucleotide metabolism. Cancer Chemother Rep 23:71-85.
15. Hostetler HA, Petrescu AD, Kier AB, and Schroeder F (2005) Peroxisome proliferator-activated receptor α interacts with high affinity and is conformationally responsiveto endogenous ligands. J Biol Chem 280:18667-18682. (Pubitemid 41379567)
16. Hsu MH, Savas U, Griffin KJ, and Johnson EF (2007) Human cytochrome p450 family 4 enzymes: function, genetic variation and regulation. Drug Metab Rev 39: 515-538. (Pubitemid 47355735)
17. Hsu MH, Savas U, Lasker JM, and Johnson EF (2011) Genistein, resveratrol, and 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside induce cytochrome P450 4F2 expression through an AMP-activated protein kinase-dependent pathway.J Pharmacol Exp Ther 337:125-136.
18. Igal RA, Wang P, and Coleman RA (1997) Triacsin C blocks de novo synthesis of glycerolipids and cholesterol esters but not recycling of fatty acid into phospholipid:evidence for functionally separate pools of acyl-CoA. Biochem J 324:529-534. (Pubitemid 27267998)
19. Jacobs RL, Lingrell S, Dyck JR, and Vance DE (2007) Inhibition of hepatic phosphatidylcholine synthesis by 5-aminoimidazole-4-carboxamide-1-β-4- ribofuranoside is independent of AMP-activated protein kinase activation. J Biol Chem 282:4516-4523. (Pubitemid 47100967)
20. Kersten S, Desvergne B, and Wahli W (2000) Roles of PPARs in health and disease.Nature 405:421-424. (Pubitemid 30367411)
21. Kim YD, Park KG, Lee YS, Park YY, Kim DK, Nedumaran B, Jang WG, Cho WJ, HaJ, Lee IK, et al. (2008) Metformin inhibits hepatic gluconeogenesis through AMP activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes 57:306-314.
22. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM, et al. (1997) Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferatoractivated receptors α and γ. Proc Natl Acad Sci U S A 94:4318-4323. (Pubitemid 27194239)
23. Lee P, Peng H, Gelbart T, and Beutler E (2004) The IL-6- and lipopolysaccharide-induced transcription of hepcidin in HFE-, transferrin receptor 2-, and β2-microglobulin-deficient hepatocytes. Proc Natl Acad Sci U S A 101:9263-9265. (Pubitemid 38812863)
24. Lee WJ, Kim M, Park HS, Kim HS, Jeon MJ, Oh KS, Koh EH, Won JC, Kim MS, Oh GT, et al. (2006) AMPK activation increases fatty acid oxidation in skeletal muscle by activating PPARα and PGC-1. Biochem Biophys Res Commun 340:291-295. (Pubitemid 41827679)
25. Lefebvre P, Chinetti G, Fruchart JC, and Staels B (2006) Sorting out the roles of PPAR α in energy metabolism and vascular homeostasis. J Clin Invest 116:571-580. (Pubitemid 43326861)
26. McGee SL and Hargreaves M (2010) AMPK-mediated regulation of transcription inskeletal muscle. Clin Sci (Lond) 118:507-518.
27. Noma T (2005) Dynamics of nucleotide metabolism as a supporter of life phenomena. J Med Invest 52:127-136.
28. Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, and Cravatt BF (2010) Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 140:49-61.
29. Pande SV and Mead JF (1968) Long chain fatty acid activation in subcellularpreparations from rat liver. J Biol Chem 243:352-361.
30. Pégorier JP, Le May C, and Girard J (2004) Control of gene expression by fatty acids.J Nutr 134:2444S-2449S. (Pubitemid 39201619)
31. Raucy JL and Lasker JM (1991) Isolation of P450 enzymes from human liver.Methods Enzymol 206:577-587.
32. Savas U, Machemer DE, Hsu MH, Gaynor P, Lasker JM, Tukey RH, and Johnson EF(2009) Opposing roles of peroxisome proliferator-activated receptor α and growth hormone in the regulation of CYP4A11 expression in a transgenic mouse model.J Biol Chem 284:16541-16552.
33. Soupene E and Kuypers FA (2008) Mammalian long-chain acyl-CoA synthetases.Exp Biol Med (Maywood) 233:507-521. (Pubitemid 351657352)
34. Viollet B, Mounier R, Leclerc J, Yazigi A, Foretz M, and Andreelli F (2007) Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders. Diabetes Metab 33:395-402. (Pubitemid 350218220)
35. Zang M, Xu S, Maitland-Toolan KA, Zuccollo A, Hou X, Jiang B, Wierzbicki M,Verbeuren TJ, and Cohen RA (2006) Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 55:2180-2191. (Pubitemid 44743614)
36. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, et al. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174. (Pubitemid 32995375)